Profusa Initiates Board-Led Process to Evaluate Strategic Alternatives and Maximize Shareholder Value
Rhea-AI Summary
Profusa (Nasdaq: PFSA) announced a Board-led process to evaluate strategic alternatives to maximize shareholder value, while prioritizing near-term commercial milestones. The company engaged Tungsten Advisors and is focusing on CE Mark progress for the Lumee Oxygen platform and pursuing Healthcare Research revenue.
Profusa signed an April 21, 2026 asset purchase agreement to acquire PanOmics Assay know-how from Bio Insights LLC; the transaction is subject to customary closing conditions and required stockholder approval under Nasdaq rules.
AI-generated analysis. Not financial advice.
Positive
- Board initiated a formal strategic-alternatives review (May 5, 2026)
- Engaged Tungsten Advisors as exclusive strategic financial advisor
- Completed two required GMED on-site audits for MDR conformity
- Signed Asset Purchase Agreement for PanOmics Assay know-how (Apr 21, 2026)
Negative
- No assurance the strategic review will result in any transaction
- PanOmics acquisition subject to stockholder approval and closing conditions
- CE Mark outcome timing uncertain; GMED process anticipated in Q3–early Q4
- Potential issuance of securities may trigger Nasdaq approval and dilution
News Market Reaction – PFSA
On the day this news was published, PFSA declined 6.64%, reflecting a notable negative market reaction. Argus tracked a peak move of +8.6% during that session. Argus tracked a trough of -24.7% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $175K from the company's valuation, bringing the market cap to $2.46M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
PFSA is down 0.8% while key peers show mixed moves (e.g., ALUR up 11.27%, AIMD down 1.16%, others flat). With no peers in the momentum scanner and no same-day peer news, trading appears stock-specific rather than sector-driven.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| 2026-04-06 | PanOmics LOI announcement | Positive | +144.1% | LOI to acquire PanOmics multi-omics platform for equity consideration. |
| 2026-02-27 | Offering strategy change | Negative | -14.8% | Withdrawal of $15M S-1 public offering to pursue smaller raise. |
| 2026-02-19 | Guidance raise & orders | Positive | -4.5% | European purchase orders and increased 2026 revenue guidance for Lumee. |
| 2026-02-12 | Mayo collaboration | Positive | -33.4% | Know-how agreement with Mayo Clinic on Lumee oxygen monitoring uses. |
| 2026-02-05 | Reverse stock split | Negative | -36.4% | 1-for-75 reverse split to reduce share count and maintain listing. |
Recent history shows sharp selling on several positive operational updates, with only the PanOmics LOI prompting a strong upside move.
Over the last few months, Profusa announced several notable developments. A 1-for-75 reverse split in early February and subsequent governance and financing steps framed its transition as a public company. Operationally, the company disclosed a Mayo Clinic collaboration and European purchase orders for the Lumee™ Oxygen system, plus raised 2026 revenue guidance, yet those updates were followed by negative price reactions. In contrast, an April 2026 Letter of Intent for a PanOmics multi-omics platform triggered a strong positive move. Today’s strategic review and CE Mark progress fit into this capital- and growth-focused trajectory.
Market Pulse Summary
The stock moved -6.6% in the session following this news. A negative reaction despite the strategic review and CE Mark progress would fit a pattern where prior positive updates were followed by selling. Earlier announcements around Mayo Clinic collaboration and raised revenue guidance saw share price declines, even as the company expanded its Lumee platform. Investors may be weighing dilution and execution risks tied to capital formation and acquisitions against long-term potential, making outcomes of the strategic alternatives process and regulatory milestones important watchpoints.
Key Terms
ce mark regulatory
eu medical device regulation regulatory
ngs technical
multi-omics technical
precision medicine medical
asset purchase agreement financial
AI-generated analysis. Not financial advice.
Company focusing resources on near-term commercial milestones; European CE Mark process and Healthcare Research revenue opportunities
Process intended to evaluate strategic growth alternatives to enhance scale, strengthen execution and support long-term shareholder value creation
BERKELEY, CA, May 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announced that its Board of Directors has initiated a Board-led process to evaluate strategic alternatives intended to maximize shareholder value and support the Company’s highest-priority commercial, regulatory and platform-expansion initiatives.
The process will evaluate a range of potential opportunities, including asset-level transactions, commercial and strategic partnerships, business combinations and other corporate transactions.
Profusa has engaged Tungsten Advisors as its exclusive strategic financial advisor in connection with this process. There can be no assurance that this process will result in any transaction or other strategic outcome. Profusa does not intend to provide updates unless and until the Board of Directors approves a specific action or otherwise determines that disclosure is appropriate or required.
Concurrently, Profusa is aligning its resources and capital allocation priorities around initiatives the Company believes can best support near-term execution and value creation, including advancing European CE Mark approval through GMED under the EU Medical Device Regulation (“MDR”);and pursuing research-use-only revenue opportunities through its Healthcare Research business.
“Profusa’s priority is to concentrate the Company around the assets, milestones and strategic opportunities we believe can drive the greatest long-term value for stockholders,” said Ben Hwang, Ph.D., Chairman and Chief Executive Officer of Profusa. “Our near-term priorities are clear: advance the Lumee Oxygen platform toward European commercialization and build revenue opportunities through our Healthcare Research business.”
Dr. Hwang continued, “The Board’s decision to evaluate strategic growth alternatives is intended to ensure a disciplined and proactive approach to scale, platform expansion and capital formation. We believe Profusa has multiple strategic pathways to accelerate commercialization and strengthen the Company’s long-term position, and we intend to evaluate those opportunities with a focus on execution, financial discipline and shareholder value. Tungsten Advisors brings the sector expertise, senior-level execution capabilities and corporate finance perspective we believe can help us identify, structure and pursue strategic pathways that can expand our platform capabilities, accelerate commercialization, support capital formation, and strengthen long-term shareholder value.
Regulatory and Commercial Update
Profusa has successfully completed the two required on-site audits conducted by its European Notified Body, GMED, as part of the MDR conformity assessment process for the Lumee Oxygen platform. The Company is actively addressing feedback received during the review process and continues to advance toward potential CE Mark certification. Profusa continues to make significant progress toward CE marking for the Lumee Oxygen platform and anticipates that GMED will complete its process in Q3 or early Q4.
PanOmics Assay Asset Purchase Agreement
On April 21, 2026, Profusa entered into an Asset Purchase Agreement with Bio Insights LLC pursuant to which Profusa agreed to acquire substantially all know-how assets related to the PanOmics Assay, an integrated, NGS multi-omics analysis platform combining genomics, transcriptomics, metabolomics and related fields used in drug discovery and precision medicine.
The Company believes the PanOmics Assay can complement Profusa’s existing biosensing platform by expanding its capabilities across precision diagnostics, multi-omics analysis and data-driven healthcare applications. The transaction remains subject to customary closing conditions, including stockholder approval of the issuance of securities in connection with the transaction, as required by applicable Nasdaq rules.
About Tungsten Advisors
Tungsten Advisors (www.tungstenadv.com) is an investment banking firm focused on strategic advisory and corporate finance for healthcare and technology companies. Tungsten provides transactional services including financings (private placements/PIPEs), corporate licensing and mergers and acquisitions (M&A). Tungsten also focuses on company incubation and makes direct investments alongside the creation of new companies in healthcare and technology.
Securities offered through Finalis Securities LLC Member FINRA/SIPC. Tungsten Partners LLC d/b/a Tungsten Advisors and Finalis Securities LLC are separate, unaffiliated entities.
About Profusa
Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements including, without limitation, risks related to the Company's planned European and U.S. product launches, the risk that such product launches may not result in revenue at the levels anticipated, the risk that customer demand may be less than expected, and risks relating to the Company’s withdrawal of the Registration Statement and conducting a smaller offering of its securities. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management, are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described more fully in the Company's public filings made by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.
Contacts
Investor and Media Contacts
email: investors@profusa.com
phone: 516 222 2560
